Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases

Expert Opinion on Pharmacotherapy
R P DanisT A Ciulla

Abstract

Antisense oligonucleotides are a class of compounds being developed as therapeutic agents for many types of diseases. Although still relatively early in the clinical characterisation, the power of this technology lies in the ability to utilise genetic information and the known molecular mechanisms of disease to foster efficient and rational drug design. Consideration of novel approaches to treating ocular diseases is of interest because there are many ocular diseases with no satisfactory treatments. The recent availability of animal models of many ocular diseases provides the opportunity to use antisense oligonucleotides to understand the mechanisms of disease pathology and to potentially intervene therapeutically in ocular disease. There are already a number of examples where antisense oligonucleotides have been applied to the study of ocular physiology and disease and there is an antisense oligonucleotide approved for the treatment of cytomegalovirus (CMV) retinitis. We summarise current research in this area and highlight the properties of these compounds that are favourable for use as ocular therapeutics.

References

Oct 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalP C Zamecnik
Nov 7, 1995·Proceedings of the National Academy of Sciences of the United States of America·L P AielloL E Smith
Dec 1, 1995·Science·M FriedlanderD A Cheresh
Nov 1, 1995·Nature Medicine·C A Stein
Apr 6, 1995·Nature·A M KriegD M Klinman
Jan 1, 1995·Clinical Pharmacokinetics·S AgrawalJ Tang
Sep 1, 1993·Current Eye Research·J T Rosenbaum, R S Boney
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·N M Dean, R McKay
May 14, 1996·Proceedings of the National Academy of Sciences of the United States of America·G S RobinsonL E Smith
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·M FriedlanderD A Cheresh
Jan 1, 1996·Antisense & Nucleic Acid Drug Development·A M KriegE Fisher
Oct 29, 1996·Proceedings of the National Academy of Sciences of the United States of America·D W Rickman, C Bowes Rickman
Jan 1, 1996·Antisense & Nucleic Acid Drug Development·P E RakoczyI Constable
Nov 12, 1996·Proceedings of the National Academy of Sciences of the United States of America·H SierakowskaR Kole
Feb 20, 1997·Nature·J W Nyce, W J Metzger
Apr 19, 1997·Lancet·A WebbZ Dziewanowska
Apr 18, 1998·Nature Medicine·D A Cheresh
May 21, 1998·Antisense & Nucleic Acid Drug Development·D M Klinman
Apr 8, 1999·Drugs·C M Perry, J A Balfour
Jun 23, 1999·Proceedings of the National Academy of Sciences of the United States of America·R B NussenblattS M Whitcup
Feb 1, 2000·Molecular Medicine Today·S Agrawal, E R Kandimalla
Feb 24, 2000·Nucleic Acids Research·T A VickersS M Freier
May 12, 2000·Biochimica Et Biophysica Acta·S T Crooke
May 12, 2000·Biochimica Et Biophysica Acta·J Summerton

❮ Previous
Next ❯

Citations

Jan 25, 2011·Expert Opinion on Therapeutic Targets·Ghulam Mohammad, Renu A Kowluru
Sep 24, 2004·Trends in Pharmacological Sciences·Scott P HenryNicholas M Dean
May 4, 2016·Molecular Therapy. Nucleic Acids·Rosie Z YuScott Henry
Jun 10, 2010·Veterinary Dermatology·Nobuo MurayamaTsuneo Fukata
Jul 28, 2019·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Noah PostYanfeng Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.